Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Insider Sells $21,353.10 in Stock

Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Get Rating) insider Hunter Gillies sold 1,090 shares of Aerovate Therapeutics stock in a transaction on Wednesday, May 17th. The shares were sold at an average price of $19.59, for a total transaction of $21,353.10. Following the completion of the transaction, the insider now owns 3,251 shares in the company, valued at approximately $63,687.09. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Hunter Gillies also recently made the following trade(s):

• On Friday, April 21st, Hunter Gillies sold 4,000 shares of Aerovate Therapeutics stock. The shares were sold at an average price of $19.50, for a total transaction of $78,000.00.

Aerovate Therapeutics Trading Down 3.3 %

NASDAQ:AVTE opened at $18.54 on Monday. The firm has a market capitalization of $459.98 million, a price-to-earnings ratio of -7.96 and a beta of 0.34. The firm’s fifty day simple moving average is $20.00 and its 200 day simple moving average is $22.25. Aerovate Therapeutics, Inc. has a twelve month low of $11.13 and a twelve month high of $30.79.

Hedge Funds Weigh In On Aerovate Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Rhumbline Advisers lifted its holdings in shares of Aerovate Therapeutics by 4.0% during the 1st quarter. Rhumbline Advisers now owns 14,798 shares of the company’s stock valued at $298,000 after acquiring an additional 566 shares in the last quarter. Barclays PLC lifted its holdings in Aerovate Therapeutics by 22.0% in the 1st quarter. Barclays PLC now owns 4,720 shares of the company’s stock worth $94,000 after buying an additional 850 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Aerovate Therapeutics by 3.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 24,641 shares of the company’s stock worth $722,000 after buying an additional 885 shares in the last quarter. American International Group Inc. lifted its holdings in Aerovate Therapeutics by 21.3% in the 1st quarter. American International Group Inc. now owns 6,494 shares of the company’s stock worth $119,000 after buying an additional 1,140 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in Aerovate Therapeutics by 136.2% in the 1st quarter. Tower Research Capital LLC TRC now owns 2,702 shares of the company’s stock worth $55,000 after buying an additional 1,558 shares in the last quarter.

Analyst Upgrades and Downgrades

Separately, Guggenheim assumed coverage on shares of Aerovate Therapeutics in a report on Tuesday, February 28th. They set a “buy” rating and a $36.00 target price on the stock.

About Aerovate Therapeutics

(Get Rating)

Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.